0001562180-20-005777.txt : 20200902 0001562180-20-005777.hdr.sgml : 20200902 20200902200143 ACCESSION NUMBER: 0001562180-20-005777 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200831 FILED AS OF DATE: 20200902 DATE AS OF CHANGE: 20200902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: THERO JOHN F CENTRAL INDEX KEY: 0001199637 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21392 FILM NUMBER: 201158072 MAIL ADDRESS: STREET 1: C/O AMARIN PHARMA, INC. STREET 2: 1430 ROUTE 6 CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMARIN CORP PLC\UK CENTRAL INDEX KEY: 0000897448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C STREET 2: 77 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 BUSINESS PHONE: 353 1 6699 020 MAIL ADDRESS: STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C STREET 2: 77 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 FORMER COMPANY: FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC DATE OF NAME CHANGE: 20000201 FORMER COMPANY: FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC DATE OF NAME CHANGE: 19930322 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-08-31 false 0000897448 AMARIN CORP PLC\UK AMRN 0001199637 THERO JOHN F C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22 BRIDGEWATER NJ 08807 true true false false President and CEO Ordinary Shares 2020-08-31 4 M false 6736.00 A 2528025.00 D Ordinary Shares 2020-08-31 4 M false 6736.00 A 2534761.00 D Ordinary Shares 2020-08-31 4 F false 5302.00 7.36 D 2529459.00 D Restricted Stock Units 0.00 2020-08-31 4 M false 6736.00 0.00 D Ordinary Shares 6736.00 80833.00 D Restricted Stock Units 0.00 2020-08-31 4 M false 6736.00 0.00 D Ordinary Shares 6736.00 80833.00 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fourth vesting event occurred on August 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. Not applicable. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Please see the section titled "Remarks" below for additional information. Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 9,524,590 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Plan, including but not limited to certain performance-based RSUs that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time. /s/ John F. Thero 2020-09-02